Status: MediSieve’s frontline product targets IL-6 driven hyperinflammation, present in many patients including those suffering from sepsis, cytokine release syndrome (a common side-effect of CAR-T cell immunotherapy), and COVID-19. The beads for IL-6 are at the pre-clinical stage. We expect to start randomised control trials in 2021.

Status: For Severe Sepsis, we are developing the “Sepsis Cocktail”, which is a combination of several MediSieve Beads. This will treat the dysregulated immune response which is characteristic of Sepsis, as well as its inital trigger. The beads for sepsis cocktail are at in vitro demonstration stage. We are planning to start pre-clinical trials in 2022.

Status: The beads for leukaemia are at in vitro demonstration stage.